Skip to main content
OpenTrials
Completed

NCT Number: NCT02514486

Assessment of Cancer Concerns at the End of Treatment (ACE)

This study will describe patient-reported symptom burden and concerns, quality of life (QOL), and health behaviors of breast cancer(BC) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate provider satisfaction following delivery of an electronic health record (HER)/EPIC summary of these PROs. Secondary aims will estimate differences in referral to available services between those providers exposed to the PRO summary and historical controls. BC survivors who have completed initial treatment and present within the first year following treatment for an end of treatment (EOT)/survivorship focused visit will be the focus of this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer(BC) Survivors

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with invasive, non-metastatic BC (Stage I, II, or III) without hematogenous or distant metastases
  • Have completed initial treatment (chemotherapy, radiotherapy, and/or surgery). May still be receiving hormonal or targeted therapy (e.g., tamoxifen, aromatase inhibitors).
  • Within 1 year of completing primary treatment
  • Scheduled for an EOT visit
  • Age 18 years or older
  • Can understand written English
  • Have internet access and a working email address

Exclusion criteria

  • Diagnosed with non-invasive (Stage 0/DCIS) or metastatic (Stage IV) cancer or hematogenous or distant metastatic disease
  • No working email address -

Treatment and study plan

Questionnaire

Behavioral

Primary outcomes

  1. Completion of Questionnaire

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Abramson Cancer Center at Penn Medicine

Other

Registry information

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Aug 3, 2015
Registry last updated
Apr 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.